The CMA Is Watching: Why Danone's £870M Huel Deal Is a Test Case for Big Food Nutrition M&A

The UK Competition and Markets Authority closes its public comment window at 5pm BST on 10 June 2026. The subject: Danone's planned €1 billion acquisition of Huel, the British meal replacement and complete nutrition brand. Once that window shuts, a formal Phase 1 investigation is expected to follow. The CMA has not yet launched one — what has happened so far is a pre-investigation information-gathering step, the regulatory equivalent of clearing the desk before the real work begins.

The outcome will matter far beyond Danone and Huel. It will become the reference point for how European regulators approach every future attempt by a major food multinational to acquire a fast-growing challenger brand in functional nutrition.

What the CMA Is Actually Looking At

Danone announced the deal in March 2026 as a core plank of its Renew Danone strategy — a deliberate pivot toward functional and complete nutrition categories. At £870 million, the valuation prices Huel at roughly 3.5x its FY2025 revenue of £250 million and 44x its pre-tax profit of £19.4 million. On a pure earnings multiple, that is an aggressive price. On a strategic platform multiple — DTC infrastructure, subscriber data, proprietary logistics — it is more defensible.

The CMA's concern is not a traditional overlap question. Danone and Huel do not stock the same shelf in significant volume. The regulator is asking something harder: whether Danone's scale in dairy, plant-based, and functional food would reduce competitive pressure in a category where Huel has, as an independent brand, been forcing incumbents to move faster on innovation, pricing, and product development.

Put simply: does Huel inside Danone compete as hard as Huel outside Danone? If the answer is no, the deal may fail the test even with minimal direct market share overlap.

What Huel Actually Built

Huel is not a startup. In FY2025, the company reported revenues of £250 million, with UK sales rising 26.5% year-on-year to £139.3 million. Pre-tax profits came in at £19.4 million. Retail presence reached more than 25,000 locations globally, including approximately 70% of UK supermarkets. Wholesale revenue grew from £5.7 million in FY2024 to £12.4 million in FY2025 and is on track to exceed £20 million in 2026.

DTC subscription is still the core of the model — but Huel has de-risked channel concentration without compromising margin. That combination of subscription stickiness and broadening retail footprint is precisely the infrastructure Danone is buying. Building it from scratch at equivalent scale would take years and significant capital deployment.

The global meal replacement market was valued at $15.6 billion in 2024 and is projected to reach $28.5 billion by 2033, growing at approximately 7.5% annually. Danone is not chasing a speculative trend. It is acquiring a proven position in a category with a decade of structural tailwinds behind it.

The Broader Pattern Behind This Review

The Danone/Huel case does not sit in isolation. In January 2026, the CMA fast-tracked Associated British Foods' acquisition of Hovis directly to Phase 2 — bypassing the standard Phase 1 review entirely. The Phase 2 statutory deadline for that case runs to 24 June 2026. The message from that decision was clear: the CMA is prepared to escalate food M&A scrutiny without hesitation, and without the customary grace period of a Phase 1 clearance attempt.

The regulatory pattern emerging across the UK and EU is consistent. Regulators are no longer only looking at horizontal market share overlap. They are asking whether large incumbents systematically reduce competition by acquiring the challenger brands that were driving innovation rather than competing with them directly. In functional nutrition — a category still early in its consolidation arc — that question is live, material, and likely to be repeated.

A Phase 1 clearance would confirm that regulators accept the strategic rationale: Danone's resources can accelerate Huel's growth in ways independent ownership cannot. A Phase 2 referral sends the opposite signal: that Huel's independence creates more competitive value than Danone's scale can justify replacing it.

Either outcome becomes case law for every nutritional platform acquisition that follows. Nestlé, Lactalis, Arla, FrieslandCampina — any of which could plausibly pursue a DTC nutrition acquisition in the next 24 months — will model their deals against the Danone/Huel precedent.

What the Decision Means for Operators and Investors

Three structural facts that matter regardless of how the CMA rules. First, functional nutrition is now a merger control category in Europe, not just a commercial growth trend. Any exit from a PE-backed nutrition platform routed through a Big Food strategic buyer requires pre-transaction merger control work, not post-signing damage control.

Second, the €1 billion price for £250 million in revenue has been placed in front of regulators and not challenged on proportionality grounds. That is the new comp for European functional nutrition M&A. PE-backed platforms with comparable revenue profiles will be priced against it.

Third, the CMA's framing confirms that DTC infrastructure — subscriber relationships, proprietary data, channel-independent logistics — has antitrust standing. It is not just a business model advantage. It is a competitive asset that regulators consider worth protecting independently of shelf presence or market share percentages.

The decision will come in the weeks following 10 June. When it does, it will be the most instructive regulatory data point food and beverage investors have seen in functional nutrition in years. Watch it closely.